| 1 | LDLR, PAQR3, PCSK9
|
| PAQR3 modulates blood cholesterol level by facilitating interaction between LDLR and PCSK9.
|
| Huang M, Zhao Z, Cao Q, You X, Wei S, Zhao J, Bai M, Chen Y.
|
| Metabolism. May;94:88-95. doi: 10.1016/j.metabol.2019.02.005. Epub 2019 Mar 1. 2019
|
| 2 | PCSK9
|
| Fetal gender and gestational age differentially affect PCSK9 levels in intrauterine growth restriction.
|
| Pecks U, Rath W, Maass N, Berger B, Lueg I, Farrokh A, Farrokh S, Eckmann-Scholz C.
|
| Lipids Health Dis 15(1):193.
2016
|
| 3 | PCSK9
|
| The Role of Proprotein Convertase Subtilisin/Kexin Type 9 in Nephrotic Syndrome-Associated Hypercholesterolemia.
|
| Haas ME, Levenson AE, Sun X, Liao WH, Rutkowski JM, de Ferranti SD, Schumacher VA, Scherer PE, Salant DJ, Biddinger SB.
|
| Circulation 134(1):61-72. doi: 10.1161/CIRCULATIONAHA.115.020912.
2016
|
| 4 | PCSK9
|
| Suppressor of Cytokine Signaling-3 (SOCS-3) Induces Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Expression in Hepatic HepG2 Cell Line.
|
| Ruscica M, Ricci C, Macchi C, Magni P, Cristofani R, Liu J, Corsini A, Ferri N.
|
| J Biol Chem 291(7):3508-19. doi: 10.1074/jbc.M115.664706. Epub 2015 Dec 14.
2016
|
| 5 | HCHOLA3, PCSK9
|
| Lipoprotein(a) in Familial Hypercholesterolemia With Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Gain-of-Function Mutations.
|
| Tada H, Kawashiri MA, Yoshida T, Teramoto R, Nohara A, Konno T, Inazu A, Mabuchi H, Yamagishi M, Hayashi K.
|
| Circ J 80(2):512-8. doi: 10.1253/circj.CJ-15-0999. Epub 2015 Dec 2.
2016
|
| 6 | PCSK9
|
| Local effects of human PCSK9 on the atherosclerotic lesion.
|
| Giunzioni I, Tavori H, Covarrubias R, Major AS, Ding L, Zhang Y, DeVay RM, Hong L, Fan D, Predazzi IM, Rashid S, Linton MF, Fazio S.
|
| J Pathol 238(1):52-62. doi: 10.1002/path.4630. Epub 2015 Nov 13.
2016
|
| 7 | HMGCR, PCSK9
|
| Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes.
|
| Ference BA, Robinson JG, Brook RD, Catapano AL, Chapman MJ, Neff DR, Voros S, Giugliano RP, Davey Smith G, Fazio S, Sabatine MS.
|
| N Engl J Med 375(22):2144-2153.
2016
|
| 8 | PCSK9
|
| Identification of PCSK9 as a novel serum biomarker for the prenatal diagnosis of neural tube defects using iTRAQ quantitative proteomics.
|
| An D, Wei X, Li H, Gu H, Huang T, Zhao G, Liu B, Wang W, Chen L, Ma W, Zhang H, Cao S, Yuan Z.
|
| Sci Rep 5:17559. doi: 10.1038/srep17559.
2015
|
| 9 | HSP90B1, LDLR, PCSK9
|
| GRP94 Regulates Circulating Cholesterol Levels through Blockade of PCSK9-Induced LDLR Degradation.
|
| Poirier S, Mamarbachi M, Chen WT, Lee AS, Mayer G.
|
| Cell Rep 13(10):2064-71. doi: 10.1016/j.celrep.2015.11.006. Epub 2015 Nov 25.
2015
|
| 10 | OLR1, PCSK9
|
| Cross-talk between LOX-1 and PCSK9 in vascular tissues.
|
| Ding Z, Liu S, Wang X, Deng X, Fan Y, Shahanawaz J, Shmookler Reis RJ, Varughese KI, Sawamura T, Mehta JL.
|
| Cardiovasc Res 107(4):556-67. doi: 10.1093/cvr/cvv178. Epub 2015 Jun 19.
2015
|
| 11 | PCSK9
|
| PCSK9 regulates apoptosis in human neuroglioma u251 cells via mitochondrial signaling pathways.
|
| Piao MX, Bai JW, Zhang PF, Zhang YZ.
|
| Int J Clin Exp Pathol 8(3):2787-94. eCollection 2015.
2015
|
| 12 | PCSK9
|
| PCSK9 and its modulation.
|
| Cui CJ, Li S, Li JJ.
|
| Clin Chim Acta 440:79-86. doi: 10.1016/j.cca.2014.10.044. Epub 2014 Nov 6. Review.
2015
|
| 13 | CFAP44, PCSK9
|
| The rs13064411 polymorphism in the WDR52 gene, associated with PCSK9 levels, modifies statin-induced changes in serum total and LDL cholesterol levels.
|
| de Keyser CE, Becker ML, Hofman A, Lous JJ, Uitterlinden AG, Visser LE, Stricker BH.
|
| Pharmacogenet Genomics 25(3):134-42. doi: 10.1097/FPC.0000000000000120.
2015
|
| 14 | APOB, LDLR, PCSK9, PNPLA5
|
| Whole-Exome Sequencing Identifies Rare and Low-Frequency Coding Variants Associated with LDL Cholesterol.
|
| Lange LA, Hu Y, Zhang H, Xue C, Schmidt EM, Tang ZZ, Bizon C, Lange EM, Smith JD, Turner EH, Jun G, Kang HM, Peloso G, Auer P, Li KP, Flannick J, Zhang J, Fuchsberger C, Gaulton K, Lindgren C, Locke A, Manning A, Sim X, Rivas MA, Holmen OL, Gottesman O, Lu Y, Ruderfer D, Stahl EA, Duan Q, Li Y, Durda P, Jiao S, Isaacs A, Hofman A, Bis JC, Correa A, Griswold ME, Jakobsdottir J, Smith AV, Schreiner PJ, Feitosa MF, Zhang Q, Huffman JE, Crosby J, Wassel CL, Do R, Franceschini N, Martin LW, Robinson JG, Assimes TL, Crosslin DR, Rosenthal EA, Tsai M, Rieder MJ, Farlow DN, Folsom AR, Lumley T, Fox ER, Carlson CS, Peters U, Jackson RD, van Duijn CM, Uitterlinden AG, Levy D, Rotter JI, Taylor HA, Gudnason V Jr, Siscovick DS, Fornage M, Borecki IB, Hayward C, Rudan I, Chen YE, Bottinger EP, Loos RJ, Sætrom P, Hveem K, Boehnke M, Groop L, McCarthy M, Meitinger T, Ballantyne CM, Gabriel SB, O'Donnell CJ, Post WS, North KE, Reiner AP, Boerwinkle E, Psaty BM, Altshuler D, Kathiresan S, Lin DY, Jarvik GP, Cupples LA, Kooperberg C, Wilson JG, Nickerson DA, Abecasis GR, Rich SS, Tracy RP, Willer CJ; NHLBI Grand Opportunity Exome Sequencing Project.
|
| Am J Hum Genet 94(2):233-45. doi: 10.1016/j.ajhg.2014.01.010.
2014
|
| 15 | PCSK9
|
| Thyroid hormone reduces PCSK9 and stimulates bile acid synthesis in humans.
|
| Bonde Y, Breuer O, Lütjohann D, Sjöberg S, Angelin B, Rudling M.
|
| J Lipid Res 55(11):2408-15. doi: 10.1194/jlr.M051664. Epub 2014 Aug 29.
2014
|
| 16 | PCSK9
|
| PCSK9 and LDLR degradation: regulatory mechanisms in circulation and in cells.
|
| Lagace TA.
|
| Curr Opin Lipidol 25(5):387-93. doi: 10.1097/MOL.0000000000000114. Review.
2014
|
| 17 | ANXA2, PCSK9
|
| Annexin A2 reduces PCSK9 protein levels via a translational mechanism and interacts with the M1 and M2 domains of PCSK9.
|
| Ly K, Saavedra YG, Canuel M, Routhier S, Desjardins R, Hamelin J, Mayne J, Lazure C, Seidah NG, Day R.
|
| J Biol Chem 289(25):17732-46. doi: 10.1074/jbc.M113.541094. Epub 2014 May 7.
2014
|
| 18 | PCSK9
|
| PCSK9: a key modulator of cardiovascular health.
|
| Seidah NG, Awan Z, Chrétien M, Mbikay M.
|
| Circ Res 114(6):1022-36. doi: 10.1161/CIRCRESAHA.114.301621. Review.
2014
|
| 19 | LDLR, PCSK9
|
| PCSK9 acts as a chaperone for the LDL receptor in the endoplasmic reticulum.
|
| Strøm TB, Tveten K, Leren TP.
|
| Biochem J 457(1):99-105. doi: 10.1042/BJ20130930.
2014
|
| 20 | LDLR, LRP1, PCSK9
|
| Proprotein convertase subtilisin/kexin type 9 (PCSK9) can mediate degradation of the low density lipoprotein receptor-related protein 1 (LRP-1).
|
| Canuel M, Sun X, Asselin MC, Paramithiotis E, Prat A, Seidah NG.
|
| PLoS One 8(5):e64145. doi: 10.1371/journal.pone.0064145. Print 2013.
2013
|
| 21 | FOXO3, PCSK9, SIRT6
|
| FoxO3 transcription factor and Sirt6 deacetylase regulate low density lipoprotein (LDL)-cholesterol homeostasis via control of the proprotein convertase subtilisin/kexin type 9 (Pcsk9) gene expression.
|
| Tao R, Xiong X, DePinho RA, Deng CX, Dong XC.
|
| J Biol Chem 288(41):29252-9. doi: 10.1074/jbc.M113.481473. Epub 2013 Aug 23.
2013
|
| 22 | PCSK9
|
| Proprotein convertase subtilisin/kexin type 9 potentially influences cholesterol uptake in macrophages and reverse cholesterol transport.
|
| Shen L, Peng HC, Nees SN, Zhao SP, Xu DY.
|
| FEBS Lett 587(9):1271-4. doi: 10.1016/j.febslet.2013.02.027. Epub 2013 Feb 24.
2013
|
| 23 | BIRC2, LDLR, PCSK9
|
| c-IAP1 binds and processes PCSK9 protein: linking the c-IAP1 in a TNF-α pathway to PCSK9-mediated LDLR degradation pathway.
|
| Xu W, Liu L, Hornby D.
|
| Molecules 17(10):12086-101. doi: 10.3390/molecules171012086.
2012
|
| 24 | LDLR, PCSK9
|
| Molecular characterization of proprotein convertase subtilisin/kexin type 9-mediated degradation of the LDLR.
|
| Wang Y, Huang Y, Hobbs HH, Cohen JC.
|
| J Lipid Res 53(9):1932-43. doi: 10.1194/jlr.M028563. Epub 2012 Jul 4.
2012
|
| 25 | PCSK9, SCNN1A, SCNN1B, SCNN1G
|
| Regulation of epithelial sodium channel trafficking by proprotein convertase subtilisin/kexin type 9 (PCSK9).
|
| Sharotri V, Collier DM, Olson DR, Zhou R, Snyder PM.
|
| J Biol Chem 287(23):19266-74. doi: 10.1074/jbc.M112.363382. Epub 2012 Apr 9.
2012
|
| 26 | PCSK9
|
| The M2 module of the Cys-His-rich domain (CHRD) of PCSK9 protein is needed for the extracellular low-density lipoprotein receptor (LDLR) degradation pathway.
|
| Saavedra YG, Day R, Seidah NG.
|
| J Biol Chem 287(52):43492-501. doi: 10.1074/jbc.M112.394023. Epub 2012 Oct 26.
2012
|
| 27 | HINFP, PCSK9
|
| The novel function of HINFP as a co-activator in sterol-regulated transcription of PCSK9 in HepG2 cells
|
| Li H, Liu J.
|
| Biochem J. May 1;443(3):757-68. doi: 10.1042/BJ20111645. 2012
|
| 28 | PCSK9
|
| Removal of acidic residues of the prodomain of PCSK9 increases its activity towards the LDL receptor.
|
| Holla ØL, Laerdahl JK, Strøm TB, Tveten K, Cameron J, Berge KE, Leren TP.
|
| Biochem Biophys Res Commun 406(2):234-8. Epub 2011 Feb 13.
2011
|
| 29 | LDLR, PCSK9
|
| Role of ubiquitination in PCSK9-mediated low-density lipoprotein receptor degradation.
|
| Chen Y, Wang H, Yu L, Yu X, Qian YW, Cao G, Wang J.
|
| Biochem Biophys Res Commun 415(3):515-8. doi: 10.1016/j.bbrc.2011.10.110. Epub 2011 Nov 2.
2011
|
| 30 | LDLR, PCSK9
|
| Mechanistic implications for LDL receptor degradation from the PCSK9/LDLR structure at neutral pH.
|
| Lo Surdo P, Bottomley MJ, Calzetta A, Settembre EC, Cirillo A, Pandit S, Ni YG, Hubbard B, Sitlani A, Carfí A.
|
| EMBO Rep 12(12):1300-5. doi: 10.1038/embor.2011.205.
2011
|
| 31 | PCSK9
|
| Effects of the prosegment and PH on the activity of PCSK9: evidence for additional processing events.
|
| Benjannet S, Luna Saavedra YG, Hamelin J, Asselin MC, Essalmani R, Pasquato A, Lemaire P, Duke G, Miao B, Duclos F, Parker R, Mayer G, Seidah NG.
|
| J Biol Chem Biol Chem. 2010 Oct 13. [Epub ahead of print]PMID: 20937814 2010
|
| 32 | PCSK9
|
| Strategies for proprotein convertase subtilisin kexin 9 modulation: a perspective on recent patents.
|
| Abifadel M, Pakradouni J, Collin M, Samson-Bouma ME, Varret M, Rabès JP, Boileau C.
|
| Expert Opin Ther Pat 20(11):1547-71. Epub 2010 Sep 17.PMID: 20849207 2010
|
| 33 | PCSK9
|
| Fasting reduces plasma proprotein convertase, subtilisin/kexin type 9 and cholesterol biosynthesis in humans.
|
| Browning JD, Horton JD.
|
| J Lipid Res 51(11):3359-63. Epub 2010 Aug 16.PMID: 20716520 2010
|
| 34 | PCSK9
|
| Disrupted recycling of the low density lipoprotein receptor by PCSK9 is not mediated by residues of the cytoplasmic domain.
|
| Strøm TB, Holla ØL, Tveten K, Cameron J, Berge KE, Leren TP.
|
| Mol Genet Metab 101(1):76-80. Epub 2010 Jun 9.PMID: 20659812 2010
|
| 35 | LDLR, PCSK9
|
| Structural and biochemical characterization of the wild type PCSK9-EGF(AB) complex and natural familial hypercholesterolemia mutants.
|
| Bottomley MJ, Cirillo A, Orsatti L, Ruggeri L, Fisher TS, Santoro JC, Cummings RT, Cubbon RM, Lo Surdo P, Calzetta A, Noto A, Baysarowich J, Mattu M, Talamo F, De Francesco R, Sparrow CP, Sitlani A, Carfí A.
|
| J Biol Chem 284(2):1313-23. Epub 2008 Nov 10.
2009
|
| 36 | HCHOLA3, PCSK9
|
| Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease.
|
| Abifadel M, Rabès JP, Devillers M, Munnich A, Erlich D, Junien C, Varret M, Boileau C.
|
| Hum Mutat 30(4):520-9. Review.
2009
|
| 37 | ABCA1, ABCG5, ABCG8, ABLP, APOB, APOB, APOC2, ARH, FDB, FHBL1, HCHOLA3, HDLDT1, LDLR, LDLRAP1, LIPAD, LPL, MTTP, PBAM, PCSK9, SLC10A2, STSL
|
| Monogenic pediatric dyslipidemias: classification, genetics and clinical spectrum.
|
| Rahalkar AR, Hegele RA.
|
| Mol Genet Metab 93(3):282-94. Epub 2007 Nov 26. Review. 2008
|
| 38 | PCSK9
|
| The Proprotein Convertase PCSK9 Induces the Degradation of Low Density Lipoprotein Receptor (LDLR) and Its Closest Family Members VLDLR and ApoER2.
|
| Poirier S, Mayer G, Benjannet S, Bergeron E, Marcinkiewicz J, Nassoury N, Mayer H, Nimpf J, Prat A, Seidah NG.
|
| J Biol Chem 283(4):2363-72. Epub 2007 Nov 26. 2008
|
| 39 | PCSK9
|
| Inflammation stimulates the expression of PCSK9.
|
| Feingold KR, Moser AH, Shigenaga JK, Patzek SM, Grunfeld C.
|
| Biochem Biophys Res Commun 374(2):341-4. Epub 2008 Jul 16.
2008
|
| 40 | PCSK9
|
| A novel splicing variant of proprotein convertase subtilisin/kexin type 9.
|
| Schmidt RJ, Zhang Y, Zhao Y, Qian YW, Wang H, Lin A, Ehsani ME, Yu X, Wang G, Singh J, Su EW, Li S, Konrad RJ, Cao G.
|
| DNA Cell Biol 27(4):183-9.PMID: 18052825 2008
|
| 41 | PCSK9
|
| Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia.
|
| Cunningham D, Danley DE, Geoghegan KF, Griffor MC, Hawkins JL, Subashi TA, Varghese AH, Ammirati MJ, Culp JS, Hoth LR, Mansour MN, McGrath KM, Seddon AP, Shenolikar S, Stutzman-Engwall KJ, Warren LC, Xia D, Qiu X.
|
| Nat Struct Mol Biol 14(5):413-9. Epub 2007 Apr 15. 2007
|
| 42 | PCSK9
|
| Plasma PCSK9 levels correlate with cholesterol in men but not in women.
|
| Mayne J, Raymond A, Chaplin A, Cousins M, Kaefer N, Gyamera-Acheampong C, Seidah NG, Mbikay M, Chretien M, Ooi TC.
|
| Biochem Biophys Res Commun 361(2):451-6. Epub 2007 Jul 18. 2007
|
| 43 | PCSK9
|
| Molecular Characterization of Loss-of-Function Mutations in PCSK9 and Identification of a Compound Heterozygote.
|
| Zhao Z, Tuakli-Wosornu Y, Lagace TA, Kinch L, Grishin NV, Horton JD, Cohen JC, Hobbs HH.
|
| Am J Hum Genet 79(3):514-23. Epub 2006 Jul 18. 2006
|
| 44 | PCSK9
|
| A Spectrum of PCSK9 Alleles Contributes to Plasma Levels of Low-Density Lipoprotein Cholesterol.
|
| Kotowski IK, Pertsemlidis A, Luke A, Cooper RS, Vega GL, Cohen JC, Hobbs HH.
|
| Am J Hum Genet 78(3):410-22. Epub 2006 Jan 20. 2006
|
| 45 | PCSK9
|
| Effect of mutations in the PCSK9 gene on the cell surface LDL receptors.
|
| Cameron J, Holla OL, Ranheim T, Kulseth MA, Berge KE, Leren TP.
|
| Hum Mol Genet 15(9):1551-8. Epub 2006 Mar 28. 2006
|
| 46 | PCSK9
|
| Is loss of function of PCSK9 a key in the protection against atherosclerotic cardiovascular disease?
|
| Reuwer A.
|
| Clin Genet 70(1):15-7. No abstract available. 2006
|
| 47 | PCSK9, HCHOLA3
|
| Hepatic PCSK9 expression is regulated by nutritional status via insulin and sterol regulatory element-binding protein 1c.
|
| Costet P, Cariou B, Lambert G, Lalanne F, Lardeux B, Jarnoux AL, Grefhorst A, Staels B, Krempf M.
|
| J Biol Chem 281(10):6211-8. Epub 2006 Jan 6. 2006
|
| 48 | PCSK9
|
| Implication of the proprotein convertase NARC-1/PCSK9 in the development of the nervous system.
|
| Poirier S, Prat A, Marcinkiewicz E, Paquin J, Chitramuthu BP, Baranowski D, Cadieux B, Bennett HP, Seidah NG.
|
| J Neurochem 98(3):838-50. 2006
|
| 49 | LDLR, PCSK9
|
| Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment.
|
| Maxwell KN, Fisher EA, Breslow JL.
|
| Proc Natl Acad Sci U S A 102(6):2069-74. Epub 2005 Jan 27. 2005
|
| 50 | PCSK9, HCHOLA3
|
| Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9.
|
| Cohen J, Pertsemlidis A, Kotowski IK, Graham R, Garcia CK, Hobbs HH.
|
| Nat Genet 37(2):161-5. Epub 2005 Jan 16. Erratum in: Nat Genet. 2005 Mar;37(3):328. 2005
|
| 51 | PCSK9, HCHOLA3
|
| Evidence for effect of mutant PCSK9 on apolipoprotein B secretion as the cause of unusually severe dominant hypercholesterolaemia.
|
| Sun XM, Eden ER, Tosi I, Neuwirth CK, Wile D, Naoumova RP, Soutar AK.
|
| Hum Mol Genet 14(9):1161-9. Epub 2005 Mar 16. 2005
|
| 52 | PCSK9, HCHOLA3
|
| Common inactivating mutations in PCSK9 cause low LDL cholesterol.
|
| Brunham L.
|
| Clin Genet 67(6):476-7. No abstract available. 2005
|
| 53 | PCSK9, HCHOLA3
|
| A mutation in PCSK9 causing autosomal-dominant hypercholesterolemia in a Utah pedigree.
|
| Timms KM, Wagner S, Samuels ME, Forbey K, Goldfine H, Jammulapati S, Skolnick MH, Hopkins PN, Hunt SC, Shattuck DM.
|
| Hum Genet 114(4):349-53. Epub 2004 Jan 15. 2004
|
| 54 | PCSK9, HCHOLA3
|
| Mutations in the PCSK9 gene in Norwegian subjects with autosomal dominant hypercholesterolemia.
|
| Leren T.
|
| Clin Genet 65(5):419-422. 2004
|
| 55 | HCHOLA3, PCSK9
|
| Mutations in PCSK9 cause autosomal dominant hypercholesterolemia.
|
| Abifadel M, Varret M, Rabes JP, Allard D, Ouguerram K, Devillers M, Cruaud C, Benjannet S, Wickham L, Erlich D, Derre A, Villeger L, Farnier M, Beucler I, Bruckert E, Chambaz J, Chanu B, Lecerf JM, Luc G, Moulin P, Weissenbach J, Prat A, Krempf M, Junien C, Seidah NG, Boileau C.
|
| Nat Genet 34(2):154-6. 2003
|
| 56 | HCHOLA3, PCSK9
|
| The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation.
|
| Seidah NG, Benjannet S, Wickham L, Marcinkiewicz J, Jasmin SB, Stifani S, Basak A, Prat A, Chretien M.
|
| Proc Natl Acad Sci U S A 100(3):928-33. Epub 2003 Jan 27. 2003
|
| 57 | PCSK9
|
| Functional characterization of Narc 1, a novel proteinase related to proteinase K.
|
| Naureckiene S, Ma L, Sreekumar K, Purandare U, Lo CF, Huang Y, Chiang LW, Grenier JM, Ozenberger BA, Jacobsen JS, Kennedy JD, DiStefano PS, Wood A, Bingham B.
|
| Arch Biochem Biophys 420(1):55-67. 2003
|